Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 104

1.

Risk of Melanoma Recurrence After Diagnosis of a High-Risk Primary Tumor.

von Schuckmann LA, Hughes MCB, Ghiasvand R, Malt M, van der Pols JC, Beesley VL, Khosrotehrani K, Smithers BM, Green AC.

JAMA Dermatol. 2019 May 1. doi: 10.1001/jamadermatol.2019.0440. [Epub ahead of print]

PMID:
31042258
2.

Sentinel lymph node biopsy followed by lymph node dissection for localised primary cutaneous melanoma.

Kyrgidis A, Tzellos T, Mocellin S, Apalla Z, Lallas A, Pilati P, Stratigos A.

Cochrane Database Syst Rev. 2015 May 16;(5):CD010307. doi: 10.1002/14651858.CD010307.pub2. Review.

3.

Early Melanoma Nodal Positivity and Biopsy Rates Before and After Implementation of the 7th Edition of the AJCC Cancer Staging Manual.

Isom C, Wheless L, Hooks MA, Kauffmann RM.

JAMA Dermatol. 2019 Mar 6. doi: 10.1001/jamadermatol.2018.5902. [Epub ahead of print]

PMID:
30840034
4.

Clinical and histopathological risk factors to predict sentinel lymph node positivity, disease-free and overall survival in clinical stages I-II AJCC skin melanoma: outcome analysis from a single-institution prospectively collected database.

Mandalà M, Imberti GL, Piazzalunga D, Belfiglio M, Labianca R, Barberis M, Marchesi L, Poletti P, Bonomi L, Novellino L, Di Biagio K, Milesi A, Guerra U, Tondini C.

Eur J Cancer. 2009 Sep;45(14):2537-45. doi: 10.1016/j.ejca.2009.05.034. Epub 2009 Jun 22.

PMID:
19553103
5.

Validation Study of the AJCC Cancer Staging Manual, Eighth Edition, Staging System for Eyelid and Periocular Squamous Cell Carcinoma.

Xu S, Sagiv O, Rubin ML, Sa HS, Tetzlaff M, Nagarajan P, Ning J, Esmaeli B.

JAMA Ophthalmol. 2019 Mar 14. doi: 10.1001/jamaophthalmol.2019.0238. [Epub ahead of print] Erratum in: JAMA Ophthalmol. 2019 May 1;137(5):587.

PMID:
30869769
6.

Axillary treatment for operable primary breast cancer.

Bromham N, Schmidt-Hansen M, Astin M, Hasler E, Reed MW.

Cochrane Database Syst Rev. 2017 Jan 4;1:CD004561. doi: 10.1002/14651858.CD004561.pub3. Review.

7.

The effect of the AJCC 7th edition change in T1 melanoma substaging on national utilization and outcomes of sentinel lymph node biopsy for thin melanoma.

Hieken TJ, Grotz TE, Comfere NI, Inselman JW, Habermann EB.

Melanoma Res. 2015 Apr;25(2):157-63. doi: 10.1097/CMR.0000000000000143.

PMID:
25647736
8.

Patterns of initial recurrence and prognosis after sentinel lymph node biopsy and selective lymphadenectomy for melanoma.

Wagner JD, Ranieri J, Evdokimow DZ, Logan T, Chuang TY, Johnson CS, Jung SH, Wenck S, Coleman JJ 3rd.

Plast Reconstr Surg. 2003 Aug;112(2):486-97.

PMID:
12900606
9.

Nodular Histologic Subtype and Ulceration are Tumor Factors Associated with High Risk of Recurrence in Sentinel Node-Negative Melanoma Patients.

Faut M, Wevers KP, van Ginkel RJ, Diercks GF, Hoekstra HJ, Kruijff S, Been LB, van Leeuwen BL.

Ann Surg Oncol. 2017 Jan;24(1):142-149. doi: 10.1245/s10434-016-5566-8. Epub 2016 Sep 19.

10.

Prognostic Predictors of Thin Melanoma in Clinico-Pathological Practice.

Roncati L, Pusiol T, Piscioli F.

Acta Dermatovenerol Croat. 2017 Jul;25(2):159-160.

PMID:
28871933
11.

Sentinel lymph node biopsy for cutaneous melanoma: the Stanford experience, 1997-2004.

Berk DR, Johnson DL, Uzieblo A, Kiernan M, Swetter SM.

Arch Dermatol. 2005 Aug;141(8):1016-22.

PMID:
16103331
12.

Association Between Patient Age and Lymph Node Positivity in Thin Melanoma.

Sinnamon AJ, Neuwirth MG, Yalamanchi P, Gimotty P, Elder DE, Xu X, Kelz RR, Roses RE, Chu EY, Ming ME, Fraker DL, Karakousis GC.

JAMA Dermatol. 2017 Sep 1;153(9):866-873. doi: 10.1001/jamadermatol.2017.2497.

13.

Concordance and Reproducibility of Melanoma Staging According to the 7th vs 8th Edition of the AJCC Cancer Staging Manual.

Elmore JG, Elder DE, Barnhill RL, Knezevich SR, Longton GM, Titus LJ, Weinstock MA, Pepe MS, Nelson HD, Reisch LM, Radick AC, Piepkorn MW.

JAMA Netw Open. 2018 May;1(1). pii: e180083. doi: 10.1001/jamanetworkopen.2018.0083.

14.

Sentinel lymph node biopsy in patients with thin primary cutaneous melanoma.

Murali R, Haydu LE, Quinn MJ, Saw RP, Shannon K, Spillane AJ, Stretch JR, Thompson JF, Scolyer RA.

Ann Surg. 2012 Jan;255(1):128-33. doi: 10.1097/SLA.0b013e3182306c72.

PMID:
21975320
15.

Should Sentinel Lymph Node Biopsy Be Performed for All T1b Melanomas in the New 8th Edition American Joint Committee on Cancer Staging System?

Egger ME, Stevenson M, Bhutiani N, Jordan AC, Scoggins CR, Philips P, Martin RC 2nd, McMasters KM.

J Am Coll Surg. 2019 Apr;228(4):466-472. doi: 10.1016/j.jamcollsurg.2018.12.030. Epub 2019 Jan 17.

PMID:
30660817
16.

Association Between NRAS and BRAF Mutational Status and Melanoma-Specific Survival Among Patients With Higher-Risk Primary Melanoma.

Thomas NE, Edmiston SN, Alexander A, Groben PA, Parrish E, Kricker A, Armstrong BK, Anton-Culver H, Gruber SB, From L, Busam KJ, Hao H, Orlow I, Kanetsky PA, Luo L, Reiner AS, Paine S, Frank JS, Bramson JI, Marrett LD, Gallagher RP, Zanetti R, Rosso S, Dwyer T, Cust AE, Ollila DW, Begg CB, Berwick M, Conway K; GEM Study Group.

JAMA Oncol. 2015 Jun;1(3):359-68. Erratum in: JAMA Oncol. 2015 Jun;1(3):285.

17.

International Validation of the American Joint Committee on Cancer's 7th Edition Classification of Uveal Melanoma.

AJCC Ophthalmic Oncology Task Force.

JAMA Ophthalmol. 2015 Apr;133(4):376-83. doi: 10.1001/jamaophthalmol.2014.5395. Erratum in: JAMA Ophthalmol. 2015 Apr;133(4):493. JAMA Ophthalmol. 2015 Sep;133(9):1096.

PMID:
25555246
18.

Natural history of melanoma in 773 patients with tumor-negative sentinel lymph nodes.

Zogakis TG, Essner R, Wang HJ, Foshag LJ, Morton DL.

Ann Surg Oncol. 2007 May;14(5):1604-11. Epub 2007 Mar 1.

PMID:
17333418
19.

Disease-Free Survival for Patients with Thin Melanomas according to the American Joint Committee on Cancer 8th Edition.

Fernández-de-Misa Cabrera, Gambra Michel LE, Uña Gorospe J, López Figueroa AL, Mullor Nogales R, Martínez Cedrés JC, Cabrera Suárez MÁ, Garrido Ríos S, Hernández Hernández N, Suárez Hernández J, Allende Riera A.

Dermatology. 2019 May 21:1-6. doi: 10.1159/000499652. [Epub ahead of print]

PMID:
31112971
20.

Favourable prognostic role of regression of primary melanoma in AJCC stage I-II patients.

Ribero S, Osella-Abate S, Sanlorenzo M, Savoia P, Astrua C, Cavaliere G, Tomasini C, Senetta R, Macripò G, Bernengo MG, Quaglino P.

Br J Dermatol. 2013 Dec;169(6):1240-5. doi: 10.1111/bjd.12586.

PMID:
23952011

Supplemental Content

Support Center